Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Jennifer Taubert
Pharma
J&J's immunology portfolio compensates for Stelara's LOE
J&J's recent growth surge has come despite the LOE of Stelara. Compensating for the shortfall is Tremfya, which topped the $2 billion mark in Q2.
Kevin Dunleavy
Jul 15, 2026 11:30am
J&J's Joaquin Duato 'optimistic' amid MFN discussions with Trump
Oct 14, 2025 11:52am
J&J logs strong innovative drug sales despite Stelara's decline
Jul 16, 2025 11:19am
J&J upholds sales growth confidence as Stelara biosims file in
Jan 22, 2025 11:26am
J&J accounts for Medicare price talks in 2030 growth projections
Jul 17, 2024 11:02am
J&J keeps the heat on Tremfya's rivals with at-home injector nod
Mar 1, 2019 10:28am
